生长分化因子15对急性冠状动脉综合征患者中期预后的预测价值

发布时间：2018-03-21 16:59

本文选题：急性冠状动脉综合征　切入点：生长分化因子　出处：《中国动脉硬化杂志》2017年05期 　论文类型：期刊论文

【摘要】：目的评估生长分化因子15(GDF-15)对急性冠状动脉综合征(ACS)患者中期预后的预测价值。方法连续入选95例急性冠状动脉综合征患者,采用酶联免疫吸附双抗体夹心法(ELISA)测定血浆GDF-15浓度,根据GDF-15中位数分为低浓度组和高浓度组,对出院患者进行定期随访,分别计算并比较2组患者的中期生存率以及主要不良心脏事件(MACE)发生率。生存率评估采用生存分析法。使用受试者工作特征(ROC)曲线分析GDF-15浓度对ACS患者的中期预后的预测价值。结果 ACS患者GDF-15浓度为921.56±462.20 ng/L,共随访患者95例,平均随访时间33.76±6.29月,死亡4例。生存分析提示GDF-15高浓度组患者的生存率低于GDF-15低浓度组(P=0.039)。GDF-15评估ACS患者中期生存的ROC曲线下面积(AUC)为0.853(SE=0.074,P=0.017,95%CI0.708~0.998),而GDF-15在预测ACS患者中期发生MACE的ROC曲线下面积为0.805(SE=0.068,P=0.000,95%CI 0.672~0.938)。结论 GDF-15可反映ACS患者的中期预后,作为一个有潜力的新标志物,能更好地帮助ACS患者进行危险分层及评估预后。
[Abstract]:Objective to evaluate the prognostic value of growth differentiation factor 15 (GDF-15) in patients with acute coronary syndrome (ACS). Methods 95 consecutive patients with acute coronary syndrome (ACS) were enrolled and plasma GDF-15 levels were measured by Elisa double antibody sandwich method. According to the median of GDF-15, the patients were divided into low concentration group and high concentration group. The medium-term survival rate and the incidence of major adverse cardiac events in the two groups were calculated and compared. Survival analysis was used to evaluate the survival rate. The medium-term preconditioning of GDF-15 concentration in ACS patients was analyzed by using the operating characteristics of the subjects. Results the concentration of GDF-15 in patients with ACS was 921.56 卤462.20 ng / L, and 95 patients were followed up. The mean follow-up time was 33.76 卤6.29 months. Survival analysis showed that the survival rate of patients with high concentration of GDF-15 was lower than that of patients with low GDF-15 concentration. The area under the ROC curve for evaluating the medium-term survival of patients with ACS was 0.853SE-0.074%. The area under the ROC curve of GDF-15 in predicting MACE in ACS patients was 0.708% 0.998g. Conclusion GDF-15 can reflect the medium-term prognosis of patients with ACS. As a potential new marker, it can better help ACS patients to carry out risk stratification and evaluate prognosis.
【作者单位】：南京医科大学附属常州市第二人民医院心内科;
【分类号】：R541.4

【相似文献】